Brendan Nagle

Type 1 Diabetic ⚡️ Functional Health
🔬 Biohacking T1D for longevity
🧪 Exploring peptides & cellular health
📈 My daily pursuit of feeling 1% better

[Brendan Nagle @bpnages25]

@AlfieJCarter CONNIE

[Brendan Nagle @bpnages25]

@mikefutia meta

[Brendan Nagle @bpnages25]

@ant0ni0_r0mer0 Hims

[Brendan Nagle @bpnages25]

@danwestworld Email

[Brendan Nagle @bpnages25]

This is what the peptide space needs more of: clinicians with actual patient volume, public reasoning, and accountability.

The next layer is transparency around sourcing, testing, and outcomes. Peptides are not a vibes category anymore. The signal is getting cleaner.

[Brendan Nagle @bpnages25]

“Peptides” is too broad to judge in one sentence.

GLP-1s have real outcome data. BPC-157/TB-500 sit in a very different evidence bucket. Cosmetic, metabolic, repair, and hormone-adjacent uses all have different risk profiles.

The useful questions are: which molecule, what purity, what dose, what endpoint, and what tradeoff?

[Brendan Nagle @bpnages25]

RFK Jr. told Joe Rogan that certain research compounds might soon be available through licensed pharmacies with a prescription from your doctor.

[Brendan Nagle @bpnages25]

This is the uncomfortable middle that gets ignored.

Skepticism of institutions does not automatically make anonymous supply chains safer.

Peptides need boring verification: identity, purity, sterility where relevant, storage, batch consistency, and clear adverse-event literacy.

Trust has to be earned on both sides.

[Brendan Nagle @bpnages25]

If you've actually been on BPC-157, we'd love to hear how it went for you, what you used it for, what worked, what didn't.

The anecdotal evidence is doing real work in this space, and more data points only help.

[Brendan Nagle @bpnages25]

Most people have heard of BPC-157 by now, but couldn't tell you much beyond the name, which is worth fixing given it has:

- 30 years of animal research behind it
- Zero toxic deaths on record
- A mountain of anecdotal evidence

BPC-157, explained: (1/14)

[Brendan Nagle @bpnages25]

Big human trials still don't exist, which is a fair knock on the peptide.

But on Feb 27, 2026, RFK Jr. went on JRE and announced BPC-157 would be moved back to legal compounding status, a sign that regulators have seen enough user reports to take it seriously.